Autio, K. A., Antonarakis, E. S., Mayer, T. M., Vaishampayan, U. N., Shevrin, D. H., Harrison, M. R., … Scher, H. I. (2018). Phase 2, randomized, 3-arm study of abiraterone acetate and prednisone (AAP), AAP plus degarelix (AAP+D), and degarelix (D) alone for patients (pts) with biochemically-recurrent prostate cancer (PC) following radical prostatectomy (RP). In Journal of Clinical Oncology (Vol. 36, pp. 5016–5016). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2018.36.15_suppl.5016

Autio, Karen A., Emmanuel S. Antonarakis, Tina M. Mayer, Ulka N. Vaishampayan, Daniel H. Shevrin, Michael Roger Harrison, Scott T. Tagawa, et al. “Phase 2, randomized, 3-arm study of abiraterone acetate and prednisone (AAP), AAP plus degarelix (AAP+D), and degarelix (D) alone for patients (pts) with biochemically-recurrent prostate cancer (PC) following radical prostatectomy (RP).” In Journal of Clinical Oncology, 36:5016–5016. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.5016.

Autio KA, Antonarakis ES, Mayer TM, Vaishampayan UN, Shevrin DH, Harrison MR, et al. Phase 2, randomized, 3-arm study of abiraterone acetate and prednisone (AAP), AAP plus degarelix (AAP+D), and degarelix (D) alone for patients (pts) with biochemically-recurrent prostate cancer (PC) following radical prostatectomy (RP). In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. 5016–5016.

Autio, Karen A., et al. “Phase 2, randomized, 3-arm study of abiraterone acetate and prednisone (AAP), AAP plus degarelix (AAP+D), and degarelix (D) alone for patients (pts) with biochemically-recurrent prostate cancer (PC) following radical prostatectomy (RP).” Journal of Clinical Oncology, vol. 36, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2018, pp. 5016–5016. Crossref, doi:10.1200/jco.2018.36.15_suppl.5016.

Autio KA, Antonarakis ES, Mayer TM, Vaishampayan UN, Shevrin DH, Harrison MR, Tagawa ST, Milowsky MI, Graff JN, Beer TM, Balar AV, Stein M, Heath EI, Armstrong AJ, Paller CJ, Nordquist LT, Dayan ES, Tse K, Heller G, Scher HI. Phase 2, randomized, 3-arm study of abiraterone acetate and prednisone (AAP), AAP plus degarelix (AAP+D), and degarelix (D) alone for patients (pts) with biochemically-recurrent prostate cancer (PC) following radical prostatectomy (RP). Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. 5016–5016.